产品
编 号：F478462
分子式：C28H24FN3O5
分子量：501.51
分子式：C28H24FN3O5
分子量：501.51
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
624
In-stock
10mg
880
In-stock
50mg
2280
In-stock
100mg
3200
In-stock
200mg
4360
In-stock
500mg
6312
In-stock
结构图
CAS No: 849217-68-1
产品详情
生物活性：
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
体内研究：
Cabozantinib (100 mg/kg, Orally, once) inhibits MET and VEGFR2 phosphorylation in mice.Cabozantinib (100 mg/kg, Orally, once) significantly increases tumor hypoxia and apoptosis.Cabozantinib (0-60 mg/kg, Orally, once daily for 14 days) inhibits tumor growth in a dose-dependent manner.Animal Model:Female mice bearing MBA-MB-231 tumor (5 per group)
Dosage:0, 100 mg/kg
Administration:Orally, once
Result:Inhibited MET and VEGFR2 phosphorylation.
Animal Model:Mice bearing MBA-MB-231 tumor
Dosage:1, 3, 10, 30, 60 mg/kg
Administration:Orally, once daily for 14 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
Cabozantinib inhibits phosphorylation of MET and VEGFR2, as well as KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 μM, respectively.Cabozantinib (4.6 nM) inhibits tubule formation with no evidence of cytotoxicity, with IC50 values of 6.7, 5.1, 4.1, 7.7, and 4.7 nM in HMVEC, MDA-MB-231, A431, HT1080, and B16F10 cells, respectively.Cabozantinib (0-370 nM, 24 h) inhibits cellular migration and invasion.Cabozantinib (48 h) inhibits tumor cell proliferation in a variety of tumor types.
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
体内研究：
Cabozantinib (100 mg/kg, Orally, once) inhibits MET and VEGFR2 phosphorylation in mice.Cabozantinib (100 mg/kg, Orally, once) significantly increases tumor hypoxia and apoptosis.Cabozantinib (0-60 mg/kg, Orally, once daily for 14 days) inhibits tumor growth in a dose-dependent manner.Animal Model:Female mice bearing MBA-MB-231 tumor (5 per group)
Dosage:0, 100 mg/kg
Administration:Orally, once
Result:Inhibited MET and VEGFR2 phosphorylation.
Animal Model:Mice bearing MBA-MB-231 tumor
Dosage:1, 3, 10, 30, 60 mg/kg
Administration:Orally, once daily for 14 days
Result:Inhibited tumor growth in a dose-dependent manner.
体外研究：
Cabozantinib inhibits phosphorylation of MET and VEGFR2, as well as KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 μM, respectively.Cabozantinib (4.6 nM) inhibits tubule formation with no evidence of cytotoxicity, with IC50 values of 6.7, 5.1, 4.1, 7.7, and 4.7 nM in HMVEC, MDA-MB-231, A431, HT1080, and B16F10 cells, respectively.Cabozantinib (0-370 nM, 24 h) inhibits cellular migration and invasion.Cabozantinib (48 h) inhibits tumor cell proliferation in a variety of tumor types.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备